- authorisedHuman Pharmacology (Phase I)- Other
A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease
This study is looking at a new medicine called MTX325 for Parkinson's disease. Researchers want to see if it's safe and how it works in healthy people and those with Parkinson's. This is an early stage of testing.
Germany · Netherlands · France - authorisedHuman Pharmacology (Phase I)- First administration to humans
A randomized, double-blind, placebo-controlled, single-ascending-dose study in healthy volunteers and a double-blind, placebo-controlled, multiple-ascending-dose study in patients with Parkinson’s disease to evaluate the safety, tolerability, and PK/PD of LY3962681.
This study is testing a new medicine, LY3962681, for Parkinson's disease. We want to see if it's safe, how well people tolerate it, and how it works in the body. It will first be given to healthy people, then to those with Parkinson's.
Germany · Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants with Parkinson’s Disease
This study is testing a new medicine, suvecaltamide, for people with Parkinson's disease who have shaking (tremor) that's affecting their daily life. It aims to see if the medicine can make their tremor better and is safe to use over 17 weeks.
Spain · Germany · Poland - recruiting
Longitudinal Investigation of I2BS in PD
This study aims to find ways to measure Parkinson's disease progression using special brain scans and spinal fluid tests. Researchers hope to understand the disease better and help develop new treatments to slow down its effects. It involves multiple visits over a year in London.
United Kingdom - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study
This study is testing a new way to give medicine for Parkinson's disease. It involves giving a special dopamine medicine directly into the brain. Researchers want to see if it's safe and helps people whose Parkinson's symptoms change a lot throughout the day.
France - active not recruitingPHASE2
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
This study looks into a new drug, BIA 28-6156, for people with Parkinson's disease linked to a specific gene change (GBA1). It aims to see if the drug can slow down the worsening of movement problems over 78 weeks, compared to a dummy drug.
United States · Canada · France - recruitingNA
Development of Digital Services for Parkinson's Disease
This study aims to improve how Parkinson's disease is diagnosed and monitored. Researchers are collecting eye movement, pupil, and walking data from people with Parkinson's and healthy volunteers. This information will help them develop new digital tools.
United Kingdom - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
This study is looking into a new medicine called prasinezumab for people with early-stage Parkinson's disease. We want to see if it's safe and helps improve symptoms compared to a dummy drug. Participants will be on a stable dose of existing Parkinson's medication.
United States · Australia · Austria - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A study to compare the absorption of two tablet strengths with the absorption of a solution.
This study is looking at how well two different strengths of a tablet are absorbed by the body compared to a liquid version. It's for people with Parkinson's disease and is a very early stage trial to understand how the medicine works in the body.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.
This study is checking if a new capsule version of a Parkinson's medicine, rasagiline, works the same as the tablet form already available. Healthy volunteers will take a single dose of each to see how the body absorbs them.
Spain - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants
This study is checking a new medicine called ARV-102 in healthy male volunteers. It's the first time this medicine is being given to people. Researchers want to see if it's safe, how the body handles it, and what effects it has, even though it's for Parkinson's disease.
Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
283PD201 (LUMA): A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease
This study is looking into a new medication called BIIB122 for Parkinson's disease. We want to see if it helps slow down the disease's effects on movement and daily activities, compared to a dummy pill. It's an important step in finding new ways to manage Parkinson's.
France · Germany · Austria - authorisedTherapeutic exploratory (Phase II)
A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson’s disease – SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial
This study is looking at a new medicine called Mirivadelgat for Parkinson's disease. We want to see how safe it is, how well it gets into the brain, and if it affects certain problems with brain cells. It's a trial where some people get the medicine and others get a dummy pill.
Norway - authorisedHuman Pharmacology (Phase I)- Other
GRoningen Early-PD Ambroxol Treatment Pharmacokinetics
This study is looking at an existing medicine called ambroxol in people with Parkinson's disease. We want to understand how the body handles this medicine early on in the disease. This could help us see if it has the potential to become a treatment for Parkinson's in the future.
Netherlands - recruiting
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
This study looks at how a Parkinson's drug, Foslevodopa/Foscarbidopa, affects the daily lives of people with advanced Parkinson's disease. We want to see how well it helps with symptoms and improves quality of life for around 100 adult patients in their everyday treatment.
United States · Israel · Romania - recruitingPHASE1
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
This study is testing a new medicine, LY3962681, for Parkinson's disease. It aims to check if the medicine is safe, well-tolerated, and how it works in both healthy people and those with Parkinson's. The medicine is given into the fluid around the spine.
United States · Germany · Japan - recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
This study looks at how well a device called the Vercise DBS System works for people with Parkinson's disease. Researchers are gathering information from around the world to see how it helps with symptoms and improves daily life.
United States · Argentina · Austria - recruitingNA
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
This study looks at how gut health, especially methane gas levels, might be linked to Parkinson's disease and memory problems. It also tests if a probiotic can help reduce methane. We want to understand if gut issues affect how these conditions develop and progress.
United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
This study is looking into a new medicine, BIA 28-6156, for people with Parkinson's disease linked to a specific gene change (GBA1). It wants to see if the medicine can slow down how the disease affects everyday activities and movement.
Germany · Netherlands · Sweden - active not recruiting
Noninterventional Study Evaluating Parkinson's Disease Diary Use
This study looks at the best way for people with Parkinson's disease to use a special diary. It checks if using the diary more often or less often makes a difference in how well it shows their symptoms. This helps understand how their Parkinson's changes over time.
United States · Canada · Germany - authorisedTherapeutic exploratory (Phase II)
Open-Label, Multi Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)
This study is looking at a new way to deliver a potential treatment, called AB-1005, for Parkinson's disease. Researchers want to make sure the delivery method is safe and works well. They'll also check if the treatment itself causes any side effects.
Poland - recruiting
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
This study looks at how well an approved Parkinson's drug, foslevodopa/foscarbidopa, works in real life for adults in Germany who are in the early stages of advanced Parkinson's. It follows participants already prescribed this medication by their doctors.
Germany - recruiting
Serotonin Release in Premotor and Motor PD
This study aims to better understand Parkinson's disease by using special brain scans. Researchers hope to find a 'biomarker' – a sign of the disease – which could help develop new medicines to slow down Parkinson's symptoms.
United Kingdom - active not recruiting
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
This study is gathering information on a new treatment called ExAblate Neuro. It uses sound waves to help people with conditions like essential tremor, Parkinson's disease, and certain types of pain. Doctors want to see how well it works and if it's safe after it's been approved for use.
United States · Canada · Israel - recruitingPhase II
DAPA-PD: a trial to test the use of dapansutrile, an anti-inflammatory medication, in people with Parkinson’s disease
This study is testing a new anti-inflammatory drug, dapansutrile, for people with early Parkinson's disease. We want to see if it can reduce brain inflammation and slow down Parkinson's progression. It's for people aged 50-80 in Cambridge, UK.
United Kingdom · England - recruitingNA
Subthalamic Nucleus, Akinesia and Parkinson's Disease
This study looks into how a tiny brain area called the subthalamic nucleus (STN) affects movement in healthy people and those with Parkinson's disease. We want to understand why movement becomes difficult in Parkinson's and how stimulating the STN might help.
France - completed
Home-based trunk intervention training to improve rigidity and functionality in people with Parkinson's disease
This study looks at how specific exercises for your body's core muscles might help people with Parkinson's disease. We want to see if these exercises can improve stiffness and make daily activities easier, compared to general exercise.
United Kingdom · England - recruiting
The LITE study: shining LIGHT on Parkinson’s disease
The LITE study is looking into Parkinson's disease (PD) to better understand its causes and how it affects people. We need volunteers, with and without PD, to help us collect important information that could lead to new treatments.
United Kingdom · Scotland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s Disease
This study is looking for healthy volunteers and people with Parkinson's disease. Researchers want to see how a new medicine, called NT-0796, works in the body and if it's safe. It's an early-stage study to understand the medicine better.
Netherlands - recruiting
Parkinson's Foundation PD GENEration Genetic Registry
This study aims to build a central collection of genetic information from people with Parkinson's disease. By understanding the genes linked to Parkinson's, researchers hope to learn more about the condition and how it develops. Participants will have genetic tests and share their results for future research.
United States · Canada · Israel - active not recruitingPHASE3
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
This study is looking at a new way to give Parkinson's medication, called ND0612, through a pump under the skin. It compares this new method to the usual tablets for people whose Parkinson's symptoms change a lot during the day.
United States · Austria · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed Rotigotine 12 mg/24 h transdermal patch in patients with Parkinson’s disease
This study is looking at how well a new patch for Parkinson's disease sticks to the skin compared to an existing patch. It's an early-stage trial focusing on how well the patches stay on for nearly a full day.
Germany - not yet recruitingPHASE2
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
This study is testing a new medicine called prasinezumab to see if it can slow down memory and thinking problems in people with Parkinson's disease who have a specific genetic change. It involves monthly infusions over two years.
France · Germany · Italy - recruiting
International Validation of Two Non-motor Scales in PD (NFS and SPARK)
This study is developing new tools to better understand how Parkinson's disease affects people, especially the hidden symptoms like mood changes and feelings of shame. It will help doctors in the future to give better care by understanding a wider range of symptoms.
France · Germany · Greece - ongoing, recruitingTherapeutic exploratory (Phase II)
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Early Parkinson's Disease
This study is testing a new medicine, Afamelanotide, for people with early Parkinson's disease. Researchers want to see if it's safe and how well it works. They'll be checking for any side effects and looking at changes in the body and brain over about eight weeks.
Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
58-week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial)
This study is looking at a new medication called Tavapadon for people with Parkinson's disease. Researchers want to see if it's safe and how well it helps with symptoms over 58 weeks. It's a Phase 3 trial, meaning it's a big step towards potentially becoming a new treatment.
France · Germany · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants
This study is giving a new medicine called DLX313 to healthy male volunteers. It's the first time humans will take this drug. Researchers want to see how the body absorbs, uses, and gets rid of it, hoping to learn more about treating Parkinson's Disease in the future.
Netherlands - authorisedTherapeutic confirmatory (Phase III)
Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE)
This study is looking into montelukast, a drug normally used for asthma, to see if it can help people with Parkinson's disease. We want to understand how safe it is and how well people tolerate it, building on earlier research.
Sweden - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease.
This study is looking at a new medicine called ARV-102 for people with Parkinson's disease. Researchers want to see if it's safe, how the body uses it, and what effects it has. It's an early-stage study, open to adults.
Netherlands - completed
Evaluating the feasibility of a samba percussion intervention for people with Parkinson’s disease
This study looks at a fun samba drumming activity for people with Parkinson's disease. It wants to see if weekly drumming sessions can help with movement, thinking, and mood. The aim is to check if a future, bigger study would be possible.
United Kingdom · Wales - recruiting
A pilot study to develop a new treatment for people living with Parkinson’s who have difficulties with producing and understanding language
This study looks into developing a new online therapy for people with Parkinson's disease who struggle with language. It's a pilot project to see if the therapy helps with daily conversations and if it's practical to offer more widely.
United Kingdom · Scotland - completed
Exploring the potential for ENGAGE-PD physical activity coaching in the NHS for people newly diagnosed with Parkinson’s: perspectives of people with lived experience of Parkinson’s
This study asks people with Parkinson's and their carers in the UK about an exercise coaching programme. It aims to adapt the American 'ENGAGE-PD' programme for the NHS to help newly diagnosed people stay active, independent, and manage their condition better.
United Kingdom · England - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Lu AF28996 in Patients With Parkinson's Disease
This study is looking into a new medicine called Lu AF28996 for people with Parkinson's disease. It's an early-stage study to check how safe the medicine is and how it works in the human body. Anyone over 18 can potentially join.
Germany · France · Spain - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients with Parkinson’s Disease
This early-stage study is looking at a new medicine called HER-096 for Parkinson's disease. Researchers want to check if it's safe and how the body handles it. It involves healthy volunteers and people with Parkinson's to see if it could be a helpful future treatment.
Finland - recruiting
Parkinson's Families Project
This study aims to find new genes linked to Parkinson's disease, especially in those with early onset or a family history. By studying families, researchers hope to better understand the condition and develop improved ways to diagnose and treat it.
United Kingdom - authorisedTherapeutic use (Phase IV)
Assessment of clozapine-related immunodeficiency effect in Parkinson's disease patients (CLOZIDPD)
This study looks at how a medicine called clozapine affects the body's infection-fighting system in people with Parkinson's disease. Researchers will check blood levels that show how well the immune system is working before and after taking clozapine for six months.
France - recruiting
Augmented reality (Reality DTx®) compared to routine physiotherapy for patients with Parkinson's
This study looks at whether special augmented reality glasses (Reality DTx®) can help people with Parkinson's disease improve their balance and walking more than usual physiotherapy. It aims to make physiotherapy more accessible and effective for daily life.
United Kingdom · England - ongoing, recruitingTherapeutic exploratory (Phase II)
A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE
This study is testing a new medicine, UCB0599, for Parkinson's disease. Researchers want to see if it's safe, how well it works long-term, and if it helps protect brain cells. They are comparing it to a dummy pill.
Netherlands · Germany · Spain - recruiting
High-intensity functional training in Parkinson's disease
This study looks at a type of exercise called High-Intensity Functional Training (HIFT) for people with Parkinson's. Researchers want to see if it's practical, enjoyable, and safe. The goal is to learn if HIFT could help manage Parkinson's symptoms.
United Kingdom · England